SCHEMBL3620368

SCHEMBL3620368

CCOC(=O)c1cc(CC)c2ccc(Cc3cccc(Cl)c3F)cn2c1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 11/20 0.43
PDE3A Q14432 11/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 2/20 0.43
GLA P06280 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.39
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
BAZ2B Q9UIF8 1/20 0.38
BAZ2A Q9UIF9 1/20 0.38
CMA1 P23946 1/20 0.38
USP2 O75604 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13316622 0.94 PDE3B (0.41) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL13316644 0.93 PDE3B (0.41) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL3627969 0.93 PDE3B (0.41) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL13316621 0.92 PDE3B (0.40) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL13316642 0.89 PDE3B (0.38) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL3628451 0.88 METTL3 (0.42) MRGPRX4CMA1
SCHEMBL13316648 0.88 PDE3B (0.38) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL13316646 0.87 CFD (0.37) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL13316657 0.87 MRGPRX4 (0.39) PDE3BPDE3AKDM4EALDH1A1GAA
SCHEMBL3625716 0.85 PDE3B (0.41) PDE3BPDE3AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745459-B2 Quinolizinone compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2010-06-29 US disclosed
US-7745459-B2 Quinolizinone compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2010-06-29 US disclosed
US-7745459-B2 Quinolizinone compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2010-06-29 US disclosed
US-20060084665-A1 Quinolizinone compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084665-A1 Quinolizinone compound and use thereof as HIV integrase inhibitor NQO2, ACE, CDK20 PDE3B 616/4885PDE3A 694/4885KDM4E 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.